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In this study susceptibility to different antimicrobial peptides was investi-
gated on colistin-susceptible and colistin-resistant identical pulsotype strains of 
KPC-2 producing Klebsiella pneumoniae ST258 as well as colistin-susceptible and 
colistin-resistant Enterobacter asburiae strains isolated from clinical samples. 
In our test, bacteria were exposed to 50 mg/ml lactoferrin, lysozyme and protamine 
– cationic antimicrobial peptides belonging to innate immune system and having 
structural similarity to polymyxins – in separate reactions. After 18 hours incuba-
tion of colonies were counted. 40% of colistin-resistant K. pneumoniae strains and 
97% of colistin-susceptible counterpart strains were lysed by protamine whereas 
87% and 100% colony forming unit decrease by lysozyme was seen, respectively. 
In the case of colistin-resistant E. asburiae strains 1 log10 cell count increase were 
observed after treatment with lysozyme and 1.56 log10 after lactoferrin exposure 
compared to the initial number whereas the colistin-susceptible showed no relevant 
cell count increase. Our fi ndings suggest that acquired colistin-resistance in Entero-
bacteriaceae is associated with tolerance against antimicrobial peptides.
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Introduction
Antimicrobial peptides and proteins are mainly cationic (i.e. rich in lysine 
and arginine residues), amphipathic polymers usually comprised of 12–45 amino 
acids, and they are part of the innate immune system of plants and animals. How-
ever, there are certain antimicrobial peptides that possess dominantly neutral or 
negative charge, but their spectrum is narrower than the cationic ones [1–3]. 
 Different studies found that their mode of action in Gram-positive bacteria is 
forming channels through the cytoplasmic membrane, causing structural disrup-
tion and fi nally, osmotic lysis. In Gram-negative microbes they initially interact 
with the lipopolysaccharide (LPS) of the outer membrane, leading to local mem-
brane disruption, then carry on forming pores through the inner cytoplasmic 
membrane [4–6]. In this capacity the antimicrobial peptides produced by multi-
cellular organisms are very similar to polymyxins (cationic decapeptides) synthe-
tized by Bacillus and Paenibacillus spp. [7–10].
Multidrug-resistant Gram-negative bacteria are being often identifi ed as 
causative agents in nosocomial infections, representing an increasing healthcare 
problem [11, 12]. These emerging multidrug-resistant pathogens set clinicians to 
constant challenges concerning the adequate therapy, and lately previously un-
heeded antibiotics such as polymyxins have been utilized against them [13–15].
Nonetheless, polymyxin-resistant Gram-negative pathogens are being 
 reported in several countries in growing frequency [16–18]. The basis of poly-
myxin-resistance in Gram-negative bacteria is the modifi cation of LPS mole-
cules of the outer membrane in such ways that the otherwise net negative charge 
of this layer grows, making it more diffi cult for positively charged agents (poly-
myxins, cationic antimicrobial peptides) to attach to it [19, 20].
In recent years there were reports about colistin-resistant and colistin-het-
eroresistant Gram-negative bacteria that developed a certain cross-resistance, 
cross-tolerance against host (i.e. human) antimicrobial peptides [21, 22]. In our 
study we describe the aforementioned phenomenon of cross-tolerance in colistin-
resistant K. pneumoniae and E. asburiae strains isolated in Hungary.
Materials and Methods
Bacterial strains
The study included K. pneumoniae and E. asburiae strains isolated in Hun-
gary. The two identical pulsetype Klebsiella strains belonged to the international 
clone ST258 were KPC-2 producers: one was colistin-susceptible and the other 
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one was colistin-resistant. They were isolated during a Hungarian outbreak in 
2008 and 2009, from upper respiratory tract and wound infections, respectively 
[23]. Three E. asburiae strains were isolated from sporadic cases of urinary tract 
infections and were identifi ed by MALDI-TOF/MS.
Antibiotic susceptibility
The minimal inhibitory concentration (MIC) values of polymyxin B (Sigma-
Aldrich) and colistin (Sigma-Aldrich) were determined by broth microdilution 
method using Mueller–Hinton broth (Becton Dickinson), and results were inter-
preted according to EUCAST documents [24].
Susceptibility to antimicrobial peptides
Each bacterial strain was incubated in 5 ml Luria–Bertani (LB) broth on 
37 °C was centrifugated with 5000 G for 15 minutes on 5 °C in their exponential 
growth phase. Bacterium solutions of 2.1×105 CFU/ml were prepared in 1 wt/vol% 
tryptone phosphate-buffered saline (T-PBS) buffer. Ten μl inocula of each bacte-
rium solution was distributed and complemented to 200 μl with protamine 
( Sigma-Aldrich), lysozyme (Sigma-Aldrich) and lactoferrin (Sigma-Aldrich), 
each with an end-concentration of 50 mg/ml. The mixtures containing lysozyme 
and protamine were incubated on 37 °C for 60 minutes, while the compounds 
with lactoferrin were incubated on 37 °C for 180 minutes. One hundred μl of 
each solution was inoculated on sterile LB agar plates, and was incubated on 
37 °C for 18 hours, then colonies were calculated log10 CFU/ml. Colony numbers 
of bacteria treated with antimicrobial peptides were compared to that of “un-
treated” ones [25].
Results
One of the two KPC-2 producing K. pneumoniae strains was resistant to 
both polymyxin B and colistin, while the other one was susceptible to the 
two agents, as interpreted according to the latest EUCAST documents. One 
E. asburiae was susceptible to polymyxins, and two were resistant however, we 
have managed to detect a sub-strain of the E. asburiae 0821 which demonstrated 
high-degree colistin-heteroresistance with E-test (Table I).
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Lactoferrin did not demonstrate any effect on either Klebsiella strains as 
there was practically no change in the colony forming unit (CFU) after treatment 
with it. Protamine exposition caused a 97% decrease in CFU of the colistin-sus-
ceptible K. pneumoniae strain, while only 40% reduction was observed with the 
colistin-resistant strain. Lysozyme showed complete bactericidal effect on the 
colistin-susceptible isolate, and its effect on the colistin-resistant one was also 
relevant, but it resulted in an only 87% diminution of CFU. These results are 
shown on Table II.
Table II. Percentile changes of K. pneumoniae CFU decrease after treatment 










K. pneumoniae col S  97% 0% 100%
K. pneumoniae col R  40% 0%  87%
Difference +57% 0% +13%
Table III. E. asburiae CFU/ml differences after treatment with different antimicrobial peptides 









E. asburiae 0821 col S 4.9 log10 4.69 log10 4.9 log10 5.11 log10
E. asburiae 0821/H col R 4 log10 4 log10 5.56 log10 5.04 log10
E. asburiae 148 col R 4.85 log10 4.85 log10 5.48 log10 5 log10
Table I. MIC values of polymyxin B and colistin in the investigated strains
MIC (μg/ml)
polymyxin B colistin
EUCAST breakpoints not determined 2
K. pneumoniae 11 <0.125 <0.125
K. pneumoniae 12 128 256
E. asburiae 0821 0.125 0.125
E. asburiae 0821/H >256 >256
E. asburiae 148 64–128 256
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The CFU/ml changes of the E. asburiae strains are listed in Table III. Ex-
posure to protamine caused no relevant difference between the initial and post-
expositional CFU. High-level tolerance to lactoferrin was observed in isolates 
0821/H and 148. Lysozyme-tolerance was detected in isolates 0821/H and 148.
Discussion
Our fi ndings on the appearance of colistin-heteroresistance within Gram-
negative bacterial strains correlate with various studies of recent years [26–28]. 
Colistin-heteroresistance concomitant with resistance to lysozyme was also pre-
viously observed in Enterobacter cloacae species [22]. The treatment of these 
polymyxin-resistant enterobacteria is a great challenge, although some recent 
studies showed that antibiotic combinations involving e.g. polymyxins, rifampic-
in, carbapenems and aminoglycosides could be effi cient [29].
Cationic antimicrobial peptides are known to bind to certain outer mem-
brane proteins (OMP), which play integral part in the effects of polymyxin anti-
biotics, as well. In Salmonella enterica serovar Typhimurium and other Gram-
negative bacteria the outer membrane bound sensor kinase PhoQ is directly 
activated by antimicrobial peptides, succeeding in phosphorylation of transcrip-
tion regulator PhoP, which activates a number of genes being important in viru-
lence, taking part in modifi cation of LPS molecules, and thus being responsible 
for developing resistance to antimicrobial peptides and polymyxins [30–34].
According to our knowledge, this is the fi rst description of simultaneous 
resistance to polymyxin-type antibiotics and cationic antimicrobial peptides in 
Hungary.
Our study suggests that prior exposure to antimicrobial peptides can infl u-
ence the development of resistance to polymyxins in bacteria. Furthermore, bac-
teria with resistance to polymyxins could also develop tolerance to antimicrobial 
peptides, which subsequently could infl uence the host defensive abilities in case 
of infections (especially in bloodstream infections), the therapeutical possibilities 
and choices, as well as the clinical outcomes.
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